Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.

Zhang, Xu; Zheng, Jiabin; Niu, Yun; Xue, Chongxiang; Yu, Yixuan; Tan, Kexin; Cui, Huijuan

Zhang, Xu; Zheng, Jiabin; Niu, Yun; Xue, Chongxiang; Yu, Yixuan; Tan, Kexin; Cui, Huijuan.

Afiliação

Zhang X; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Zheng J; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Niu Y; Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
Xue C; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Yu Y; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Tan K; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Cui H; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.

Front Immunol ; 13: 1059331, 2022.

Article em En | MEDLINE | ID: mdl-36532013

Assuntos

Neoplasias Pulmonares; Carcinoma de Pequenas Células do Pulmão; Humanos; Pessoa de Meia-Idade; Inibidores de Checkpoint Imunológico/uso terapêutico; Neoplasias Pulmonares/patologia; Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico; Carcinoma de Pequenas Células do Pulmão/patologia; Imunoterapia; Progressão da Doença

Palavras-chave

ES-SCLC; ICIs; combined regimens; long-term survival; re-challenge

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Limite: Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google